Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

Background: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic...

Full description

Bibliographic Details
Main Authors:	Giovanna Elisiana Carpagnano, Corrado Pelaia, Maria D’Amato, Nunzio Crimi, Nicola Scichilone, Giulia Scioscia, Onofrio Resta, Cecilia Calabrese, Girolamo Pelaia, Carla Maria Irene Quarato, Maria Pia Foschino Barbaro
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-06-01
Series:	Therapeutic Advances in Respiratory Disease
Online Access:	https://doi.org/10.1177/1753466620929231

Similar Items

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
by: Giovanna Elisiana Carpagnano, et al.
Published: (2021-03-01)

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
by: Giovanna Elisiana Carpagnano, et al.
Published: (2020-01-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
by: Giulia Scioscia, et al.
Published: (2020-03-01)

Adherence to omalizumab: A multicenter 'real-world' study
by: Raffaele Campisi, et al.
Published: (2020-02-01)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
by: Claudia Crimi, et al.
Published: (2020-09-01)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
by: Carpagnano GE, et al.
Published: (2019-03-01)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
by: Corrado Pelaia, et al.
Published: (2018-11-01)

Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma
by: Corrado Pelaia, et al.
Published: (2020-09-01)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
by: Pelaia C, et al.
Published: (2017-10-01)

Review: Omalizumab in the treatment of severe asthma: efficacy and current problems
by: Girolamo Pelaia, et al.
Published: (2008-12-01)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
by: Lisha Li, et al.
Published: (2021-06-01)

A survey of fungal microbiota in airways of healthy volunteer subjects from Puglia (Apulia), Italy
by: Giovanna Elisiana Carpagnano, et al.
Published: (2019-01-01)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
by: Mark C. Liu, et al.
Published: (2021-05-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
by: Diego Bagnasco, et al.
Published: (2020-08-01)

The Role of Airways 17β-Estradiol as a Biomarker of Severity in Postmenopausal Asthma: A Pilot Study
by: Giulia Scioscia, et al.
Published: (2020-06-01)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
by: Mattia Giovannini, et al.
Published: (2019-11-01)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
by: Menzella F, et al.
Published: (2017-11-01)

Molecular Targets for Biological Therapies of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2020-11-01)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
by: Pelaia C, et al.
Published: (2021-02-01)

Cost-eff ectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma
by: A. G. Tolkushin, et al.
Published: (2019-08-01)

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
by: Katrine Prætorius, et al.
Published: (2021-08-01)

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
by: Giulia Scioscia, et al.
Published: (2021-02-01)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
by: Corrado Pelaia, et al.
Published: (2018-01-01)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
by: Corrado Pelaia, et al.
Published: (2021-03-01)

Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
by: Donato Lacedonia, et al.
Published: (2021-09-01)

Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports
by: Carlo Lombardi, et al.
Published: (2020-01-01)

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2021-08-01)

Update on optimal use of omalizumab in management of asthma
by: Pelaia G, et al.
Published: (2011-06-01)

Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use [version 2; peer review: 2 approved]
by: Santi Nolasco, et al.
Published: (2020-07-01)

Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
by: Corrado Pelaia, et al.
Published: (2020-02-01)

Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications
by: Corrado Pelaia, et al.
Published: (2020-06-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
by: Diego Bagnasco, et al.
Published: (2021-02-01)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
by: Corrado Pelaia, et al.
Published: (2021-04-01)

Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension
by: Giovanna Elisiana Carpagnano, et al.
Published: (2018-01-01)

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
by: Llanos JP, et al.
Published: (2019-01-01)

Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease
by: Silvano Dragonieri, et al.
Published: (2016-01-01)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
by: Lacedonia D, et al.
Published: (2017-06-01)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
by: Pelaia C, et al.
Published: (2021-09-01)

Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
by: Campisi R, et al.
Published: (2021-05-01)

Treatment of eosinophilic myositis with mepolizumab
by: Saadia Waheed, et al.
Published: (2018-01-01)